Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sumedh Gaikwad"'
Autor:
Yvonne Schnaars, Sumedh Gaikwad, Ulrike Gottwald-Hostalek, Wolfgang Uhl, Olga Ribot, Kanthikiran V. S. Varanasi, Laura Rodríguez, Javier Torrejón, Luis Gómez
Publikováno v:
Diabetes Therapy. 14:347-362
Three studies compared the bioequivalence (BE) of new generic tablet formulations of sitagliptin (100 mg; fasting) and the fixed-dose combination (FDC) of sitagliptin/metformin (50/850 mg, 50/1000 mg; both fed) in healthy volunteers with the same tab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94abacd59ace0a84b3068ac2a60bde4c
https://doi.org/10.1007/s13300-022-01349-2
https://doi.org/10.1007/s13300-022-01349-2
Autor:
Yvonne Schnaars, Sumedh Gaikwad, Ulrike Gottwald-Hostalek, Ulrike Klingberg, Hari Kiran Chary Vadla, Vamshi Ramana Prathap
Publikováno v:
Diabetes Therapy. 13:1215-1229
Vildagliptin and metformin are two well-established oral antidiabetics with a complementary mechanism of action. Two new generic products, vildagliptin and its fixed-drug combination (FDC) with metformin, were tested for bioequivalence versus the app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f38f6866d7a91d02543cae5b723efa8
https://doi.org/10.1007/s13300-022-01269-1
https://doi.org/10.1007/s13300-022-01269-1
Publikováno v:
Clinical Pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57c0e0f3bdbd1d9df785bf63fa8643a2
https://pubmed.ncbi.nlm.nih.gov/31802401
https://pubmed.ncbi.nlm.nih.gov/31802401
Autor:
Alain, Munafo, Axel, Krebs-Brown, Sumedh, Gaikwad, Bogumila, Urgatz, Claire, Castello-Bridoux
Publikováno v:
Clinical Pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::348f0aa71ef2470b7f5578b9aacfec19
https://pubmed.ncbi.nlm.nih.gov/31187470
https://pubmed.ncbi.nlm.nih.gov/31187470
Autor:
Bikash, Medhi, Manpreet, Sukhija, Ajay, Prakash, Sumedh, Gaikwad, Vishal, Bansal, Promila, Pandhi
Publikováno v:
Pharmacological reports : PR. 60(2)
Etoricoxib is presently the most commonly prescribed cyclooxygenase-2 (Cox-2) inhibitor for chronic pain and inflammatory conditions. In clinical practice, phenytoin and etoricoxib are used in chronic conditions of generalized seizure with concomitan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::26e654f8befe23afbd395c2e385d0c8b
https://pubmed.ncbi.nlm.nih.gov/18443385
https://pubmed.ncbi.nlm.nih.gov/18443385